Related Experiment Video
Updated: Mar 22, 2026

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
New potential binding determinant for hERG channel inhibitors
P Saxena1, E-M Zangerl-Plessl1, T Linder1
1Institute of Pharmacology and Toxicology, University of Vienna, Austria.
Insights
Researchers discovered a new binding site (F557) in the hERG1 channel
Area of Science:
- Cardiovascular pharmacology
- Ion channel biophysics
- Molecular cardiology
Background:
- Human ether-à-go-go related gene (hERG) 1 channels are critical for cardiac action potential repolarization.
- Inhibition of hERG1 channels by drugs can cause life-threatening arrhythmias.
- Known binding sites for hERG1 blockers are on the pore helix and S6 segment.
Purpose of the Study:
- To investigate potential drug binding determinants on the S5 helix of hERG1 channels.
- To identify novel sites that interact with hERG1 channel blockers.
Main Methods:
- Two-microelectrode voltage clamp ionic current measurements.
- Molecular modeling techniques.
- Site-directed mutagenesis (implied by identification of specific residues).
Main Results:
- A novel high-affinity binding determinant, phenylalanine at position 557 (F557), was identified on the S5 helix.
- F557 demonstrated potency comparable to the known residue Y652.
- Molecular modeling supported a direct interaction between F557 and the outer pore helix.
Conclusions:
- The S5 helix contains a previously unrecognized aromatic binding site for hERG1 channel blockers.
- F557 represents a significant determinant for hERG1 channel blockade.
- Findings advance understanding of hERG1 channel-drug interactions and arrhythmia risk.
Abstract:
Human ether-à-go-go related gene (hERG) 1 channels conduct the rapid delayed rectifier K(+) current (IKr) and are essential for the repolarization of the cardiac action potential. hERG1 inhibition by structurally diverse drugs may lead to life threatening arrhythmia. Putative binding determinants of hERG1 channel blockers include T623, S624 and V625 on the pore helix, and residues G648, Y652 and F656, located on segment S6. We and others have previously hypothesized that additional binding determinants may be located on helix S5, which is in close contact with the S6 segments. In order to test this hypothesis, we performed a detailed investigation combining ionic current measurements with two-microelectrode voltage clamp and molecular modeling techniques. We identified a novel aromatic high affinity binding determinant for blockers located in helix S5, F557, which is equally potent as Y652. Modeling supports a direct interaction with the outer pore helix.
More Related Videos
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Related Concept Videos
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Ligand-gated Ion Channels
G-Protein Gated Ion Channels
Sensory...
GPCR Desensitization
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...